TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14365/4

Browse

Search Results

Now showing 1 - 2 of 2
  • Article
    Citation - WoS: 2
    Matrix Metalloproteinase-2 and -3 Levels in Patients With Behçet's Disease and Implication for the Presence of Vascular Aneurysm or Neurologic Involvement
    (AVES, 2023-08-24) Erten, Pınar Talu; Keser, Gökhan; Durusoy, Raika; Kocaer, Sinem Burcu; Aksu, Kenan
    Background: Behçet's disease is a systemic vasculitis affecting both arteries and veins, as well as causing recurrent inflammatory multiorgan disease. Vascular involvement is associated with increased mortality and morbidity. Matrix metalloproteinases are released at sites of inflammation and degrade various components of the extracellular matrix. Increased levels of metalloproteinase-9 and metalloproteinase- 2 have been previously reported in Behçet's disease. Methods: In this cross-sectional study, metalloproteinase-2 and metalloproteinase-3 serum levels were investigated in 103 patients with Behçet's disease and 69 healthy controls, using Invitrogen immunoassay human metalloproteinase-2 and metalloproteinase-3 ELISA kits. Results: Serum metalloproteinase-2 and metalloproteinase-3 levels were significantly higher in the Behçet's disease group compared to healthy controls. Besides, serum metalloproteinase-3 levels were significantly higher in subgroups of Behçet's disease with aneurysmal vascular involvement and with neurological involvement. However, metalloproteinase-2 and metalloproteinase-3 serum levels did not show a positive correlation with disease activity. Conclusion: Metalloproteinase-2 and -3 may contribute to the complex pathogenesis of Behçet's disease. More importantly, the detection of very high serum levels of metalloproteinase-3 may predict the formation of an aneurysm, or possibly the presence of neurological involvement in Behçet's disease and may lead the clinician to make an earlier diagnosis of these complications in young male patients with high risk.
  • Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Adrenomedullin Has No Effect on Segmental Bone Defect Healing but Increases Bone Mineral Density in Rat Model
    (AVES, 2023-10-11) Kaymakoğlu, Mehmet; Ciftci, E.; Korkusuz, P.; Ozdemir, E.; Erden, M.E.; Turhan, E.
    Objective: This study aimed to investigate the effect of adrenomedullin on the healing of the segmental bone defect in a rat model. Methods: Thirty-six Wistar rats were randomly divided into 6 groups based on follow-up periods and administered a dose of adreno-medullin hormone. In each group, bilaterally, a 2-mm bone defect was created at the diaphysis of the radius. Sodium chloride solution was administered to sham groups 3 times a week for 4 and 8 weeks intraperitoneally. Adrenomedullin was administered to the study groups 3 times a week: 15 μg—4 weeks, 15 μg—8 weeks, 30 μg—4 weeks, and 30 μg—8 weeks, respectively. After euthanasia, the segmental defects were evaluated by histomorphometric [new bone area (NBA)] and microtomographic [bone volume (BV), bone surface (BS), and bone mineral density (BMD)] analyses. Results: Although the 4-and 8-week 15 μg administered study groups had higher NBA values than the other study and control groups, the histomorphometric analysis did not reveal any statistical difference between the control and study groups regarding NBA (P >.05). In microtomographic analysis, BV was higher in the 15 μg 4-week group than 30 μg 4-week group (296.9 vs. 208.5, P =.003), and BS was lower in the 30 μg 4-week group than in the 4-week control group (695.5 vs. 1334.7, P =.005), but overall, no significant difference was found between the control and study groups (P >.05). Despite these minor differences in histomorphometric and microtomographic criteria indicating new bone formation, the BMD values of the 15 μg 8-week study group showed a significant increase compared with the control group (P =.001, respectively). Conclusion: Adrenomedullin positively affected BMD at 15 μg, but this study could not show healing in the segmental defect site at different dose regimens. Further studies are needed to assess its effects on bone tissue trauma. © 2023, AVES. All rights reserved.